Loan Repayment in Full

RNS Number : 9262J

Oxford Biomedica PLC

18 June 2014

 



Loan Repayment in Full

Oxford, UK - 18 June 2014: Oxford BioMedica ("the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announces that the Company has repaid in full the amount drawn down from the £5 million secured loan facility agreement, agreed on 19 November 2013 with the Vulpes Life Sciences Fund ("Vulpes"), the Company's largest shareholder.

On receipt of the £21.6 million (before expenses) raised through the Firm Fundraising and Open Offer, which completed on 17 June 2014, the portion of the Vulpes loan facility which had been drawn down was repaid in full by the Company. The loan agreement has been cancelled and Vulpes has released the security it was granted over certain of the Company's assets when the loan facility was entered into.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes to editors

Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

MSCQKFDBKBKDQAD